Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 2765 for:    Recruiting Studies | Psychotic Disorders | United States
Previous Study | Return to List | Next Study

Striatal Connectivity and Clinical Outcome in Psychosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02822092
Recruitment Status : Recruiting
First Posted : July 4, 2016
Last Update Posted : January 26, 2022
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Anil K. Malhotra, Northwell Health

Brief Summary:
This is an observational neuroimaging treatment study. This study involves examining the neural circuitry of controlled treatment of patients presenting with a first-episode of psychosis with risperidone or aripiprazole. Patients who present for treatment of a first psychotic episode with a schizophrenia spectrum diagnosis and who are eligible to undergo treatment with either risperidone or aripiprazole will be offered participation in the study. Clinical ratings, neuropsychological testing, neuroimaging and EEG will be conducted at baseline. Additionally, subjects will undergo the same assessments at week 12 to determine treatment-related biomarkers. Clinical ratings, including neurocognitive testing, will be conducted by blinded raters at study visits during treatment. Healthy controls (N=50) will also be recruited and scanned twice (12-week interval) to control for effects of time and practice.

Condition or disease Intervention/treatment
Psychotic Disorders Drug: Risperidone or Aripiprazole (patients only)

Detailed Description:

In this proposed study, the study will examine treatment-related effects on functional brain circuitry in first episode schizophrenia. Converging lines of evidence suggest a key role for striatal disconnectivity in the pathophysiology of psychosis. The proposed study will utilize resting state functional magnetic resonance imaging (rs-fMRI), as well as fMRI tasks derived from the Research Domain Criteria (RDoC) framework, to: 1) develop and validate a prognostic biomarker to predict antipsychotic treatment response; and 2) to model the underlying neural circuitry changes associated with state changes in psychotic symptomatology. As a prognostic biomarker, a neuroimaging assay of striatal connectivity can potentially provide a clinically useful tool to advance the goal of precision medicine. As a longitudinal index of symptom change, our model can serve as an objective index against which to measure potential efficacy of newly developed antipsychotic treatments.

A large, well-characterized cohort of patients presenting with a first episode active psychosis (regardless of DSM diagnosis) will be recruited, along with matched controls. The study will utilize two well-validated fMRI tasks capturing two portions of the positive valence system: probabilistic category learning and reward responsiveness; these tasks are designed to interrogate dorsal and ventral corticostriatal circuits, respectively. The design will be longitudinal, with two scanning sessions performed for each patient: at baseline, and after 12 weeks of treatment. Treatment will be standardized across all patients to reduce potential confounds, and healthy controls will also be scanned at baseline and 12 weeks in order to control for effects of time and practice. Level of psychotic symptomatology (hallucinations, delusions, and thought disorder) will be measured at regular intervals using a comprehensive battery of rating scales. As secondary measures, electroencephalography (EEG) will be performed coinciding with neuroimaging on a subset of patients who provide consent. We will utilize Kaplan-Meier estimators and hierarchical linear modeling to examine the association of baseline striatal connectivity, and changes in connectivity over time, with clinical response of psychotic symptoms to antipsychotic treatment. Deliverables will include both baseline and longitudinal biomarkers that can subsequently be tested in broader, more heterogeneous populations of patients with psychosis.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 170 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Striatal Connectivity and Clinical Outcome in Psychosis
Study Start Date : July 2016
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Patients with Psychotic Disorders taking Risp. or Arip.
Risperidone or aripiprazole will be administered. Subjects will start risperidone 1 mg qhs or 5mg qhs aripiprazole; on day 4 the daily dose will be increased to 2 mg risperidone or 10mg aripiprazole and to 3 mg risperidone or 15mg aripiprazole at day 7. The target dose is 3 mg risperidone or 15 mg aripiprazole daily but patients who remain psychotic can be increased to 4 mg risperidone or 20mg aripiprazole at week 4; 5 mg risperidone or 25 mg aripiprazole at week 6 and 6 mg risperidone or 30 mg aripiprazole at week 8. Study Psychiatrists will be able to increase faster if symptoms don't improve as well as decrease for side effects. These dose ranges conform with standard clinical practice and are within the FDA approved dosing ranges for schizophrenia, and schizoaffective disorder. Subjects advance in the risperidone titration schedule until they respond or develop dose-limiting side effects.
Drug: Risperidone or Aripiprazole (patients only)
Inpatients deemed eligible for the study, we be put on open-label risperidone
Other Names:
  • Risperidal
  • Aripiprazole

Healthy Volunteers
Healthy Volunteers will participate in MR imaging, Electroencephalogram , and cognitive testing.

Primary Outcome Measures :
  1. efficacy of risperidone or aripiprazole for psychotic symptoms [ Time Frame: 12 weeks ]
    To examine the efficacious treatment of psychotic symptoms with either risperidone or aripiprazole measured by specific items on the Brief Psychiatric Rating Scale - conceptual disorganization, grandiosity, hallucinatory behavior, unusual thought content

Secondary Outcome Measures :
  1. Relationship between efficacious treatment of psychotic symptoms and changes in functional connectivity of the striatum [ Time Frame: 12 weeks ]
    To examine the relationship between efficacious treatment of psychotic symptoms (measured by the Brief Psychiatric Rating Scale) and changes in functional connectivity of the striatum, calculated from fMRI scans

  2. Predicting treatment efficacy from baseline fMRI scans [ Time Frame: 12 weeks ]
    To examine whether baseline fMRI scans can predict treatment efficacy which will be measured by the Brief Psychiatric Rating Scale.

Biospecimen Retention:   Samples Without DNA
Drug Levels

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy Volunteers and Patients with Psychotic Disorders


Inclusion Criteria:

  1. current DSM-IV-defined diagnosis of schizophrenia, schizophreniform, schizoaffective disorder, brief psychotic disorder, psychotic disorder NOS, bipolar I with psychotic features (acute manic or mixed episode), major depressive disorder with psychotic features as assessed using the Structured Clinical Interview for Axis I DSM-IV Disorders (SCID-I/P) (First et al, 1994);
  2. does not meet DSM-IV criteria for a current substance-induced psychotic disorder, a psychotic disorder due to a general medical condition, delusional disorder, shared psychotic disorder, or a mood disorder without psychotic features;
  3. current positive symptoms rated ≥4 (moderate) on one or more of these BPRS (Woerner et al., 1988) items: conceptual disorganization, grandiosity, hallucinatory behavior, unusual thought content;
  4. is in a early phase of illness as defined by having taken antipsychotic medications for a cumulative lifetime period of 4 weeks or less,
  5. age 15 to 40;
  6. competent and willing to sign informed consent; and
  7. for women, negative pregnancy test and agreement to use a medically accepted birth control method.

Exclusion Criteria:

  1. serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain
  2. any medical condition which requires treatment with a medication with psychotropic effects
  3. significant risk of suicidal or homicidal behavior
  4. cognitive or language limitations, or any other factor that would preclude subjects providing informed consent
  5. medical contraindications to treatment with risperidone or aripiprazole monotherapy (e.g. neuroleptic malignant syndrome with prior risperidone exposure)
  6. lack of response to a prior adequate trial of risperidone or aripiprazole

Healthy Volunteers


  1. age 15 to 40
  2. competent to sign informed consent


  1. lifetime history of any mood disorder or any psychotic disorder as determined by clinical interview using the SCID-NP
  2. MR imaging contraindications
  3. neurologic conditions
  4. any serious non-psychiatric disorder that could affect brain functioning
  5. mental retardation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02822092

Layout table for location contacts
Contact: Anil Malhotra, MD 718-470-8012
Contact: Whitney Muscat 718-470-4152

Layout table for location information
United States, New York
Zucker Hillside Hospital Recruiting
Glen Oaks, New York, United States, 11004
Contact: Anil Malhotra, MD    718-470-8012   
Contact: Whitney Muscat    7184704152   
Sponsors and Collaborators
Northwell Health
National Institutes of Health (NIH)
Layout table for investigator information
Principal Investigator: Anil Malhotra, MD The Zucker Hillside Hospital
Layout table for additonal information
Responsible Party: Anil K. Malhotra, Psychiatry Research Department Chair, Northwell Health Identifier: NCT02822092    
Other Study ID Numbers: HS16-0411
First Posted: July 4, 2016    Key Record Dates
Last Update Posted: January 26, 2022
Last Verified: January 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Psychotic Disorders
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Antidepressive Agents
Dopamine Agonists
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin 5-HT2 Receptor Antagonists
Dopamine D2 Receptor Antagonists